Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 24, 2000

View Archived Issues

Neurobiological Technologies and UC, Berkeley sign option agreement for CRF analogues

Designer transcription factor used to activate erythropoietin gene

Medarex and Athersys form therapeutic antibody partnership

Bayer and PPL Therapeutics to jointly develop aerosol AAT formulation

Schering-Plough receives extended marketing exclusivity, submits sNDAs for loratadine

Antex Biologics signs CRADA with U.S. Navy for Campylobacter vaccine

GlycoDesign and Leo Denmark form joint venture to develop cardiovascular drugs

Altea Genomics and Elan to jointly develop DNA vaccines

Novel lymphoma marker discovered using gene expression arrays

Ultrasound contrast agent deemed approvable by the FDA

Ilex and Millennium respond to FDA letter on Campath

Cel-Sci to commence phase II Multikine study in Czech Republic

FDA approves Azulfidine EN-tabs as treatment of juvenile RA

Antigenics to acquire Aquila Biopharmaceuticals

Serotonin antagonist improves drinking behavior in early-onset alcoholism

Cancer researchers reveal extended activity of tyrosine kinase inhibitor

Parke-Davis reports SAR of nonpeptide IL-8 receptor antagonists

Orally active nonpeptide NK1 antagonist selected by Fujisawa for clinical testing

PKC inhibitors under study at Kyowa Hakko

Advanced Medicine claims novel antibiotic compounds

New nonpeptide glucagon antagonists useful for hyperglycemia, etc.

Abbott discovers novel nonpeptidic antagonists of LFA-1/ICAM-1 interaction

Novel factor Xa inhibitors under development for thromboembolic disorders

AstraZeneca receives patent for new series of pyrimidine compounds

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.